ALFRED L. GARFALL J ET AL: "Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. Abstr 8517", J. CLIN. ONCOL. SUPP., [Online] vol. 33, 2015, 2015 ASCO Annual Meeting Retrieved from the Internet: URL:http://meetinglibrary.asco.org/content /145682-156> [retrieved on 2015-12-21] (B1)

WO-A2-2010/085660 (B1)

CARPENITO CARMINE ET AL: "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 9, March 2009 (2009-03), pages 3360-3365, XP002732434, ISSN: 0027-8424 (B1)

DATABASE PROTEIN [Online] 21 November 2010 'T-cell surface glycoprotein CD3 zeta chain isoform 1 precursor [Homo sapiens].', XP003030115 Database accession no. NP_932170.1. (B1)

DATABASE PROTEIN [Online] 21 November 2010 'T-cell surface glycoprotein CD3 zeta chain isoform 2 precursor [Homo sapiens].', XP003030111 Database accession no. NP_000725. (B1)

DAVID L. PORTER ET AL.: "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, no. 8, 25 August 2011 (2011-08-25), pages 725-733, XP002732435, (B1)

Dan Margolies: "Novel cancer treatment at KU signals start of "Remarkable Revolution"", Kansas Health Institute , 10 November 2015 (2015-11-10), Retrieved from the Internet: URL:http://www.khi.org/news/article/novel- cancer-treatment-at-ku-signals-start-of-re markable-revolution [retrieved on 2015-12-21] (B1)

ERWIN M. LEE ET AL.: "Xenograft models for the preclinical valuation of new therapies in acute leukemia", LEUKEMIA & LYMPHOMA, vol. 48, no. 4, April 2007 (2007-04), pages 659-668, (B1)

IMAI ET AL.: 'Chimeric receptors with 4-188 signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.' LEUKEMIA vol. 18, no. 4, 2004, pages 676 - 684, XP002579934 (B1)

Jason Hoffman: "CTL019 Cells Demonstrate Strong Response in Pediatric Patients with Acute Lymphocytic Leukemia", PharmD ASH 2014 Oral presentation, 9 December 2014 (2014-12-09), 2014, Retrieved from the Internet: URL:http://www.cancertherapyadvisor.com/as h-2014/ctl019-acute-lymphocytic-leukemia-p ediatric-patients/article/387416/ [retrieved on 2015-12-21] (B1)

KALOS ET AL.: 'T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. 95ra73' SCI TRANSL MED. vol. 3, no. 95, 10 August 2011, pages 1 - 12, XP002667262 (B1)

MAK ISABELLA W Y ET AL: "Lost in translation: animal models and clinical trials in cancer treatment", AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, vol. 6, no. 2, 2014, pages 114-118, ISSN: 1943-8141(print) (B1)

MILONA ET AL.: 'Chimeric receptors containing CD137 signal transduction domain mediate enhanced survival of T ceils and increased antileukemic efficacy in vivo.' MOL THER vol. 17, no. 8, 2009, pages 1453 - 1464, XP055052474 (B1)

MILONE MICHAEL C ET AL: "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY AUG 2009, vol. 17, no. 8, August 2009 (2009-08), pages 1453-1464, XP002732433, ISSN: 1525-0024 (B1)

Nick Mulcahy: "'Deep Remissions' of 4 years make CAR T-cells unique in CLL", Medscape Medical News , 17 September 2015 (2015-09-17), Retrieved from the Internet: URL:http://www.medscape.com/viewarticle/85 0862 [retrieved on 2015-12-21] (B1)

PORTER ET AL.: 'Chimeric Antigen Receptor Therapy for B-cell Malignancies.' J CANCER. vol. 2, 01 June 2011, pages 331 - 332, XP055118200 (B1)

PORTER ET AL.: 'Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.' N ENGL J MED. vol. 365, no. 8, 25 August 2011, pages 725 - 733, XP055052475 (B1)

SCHUSTER STEPHEN J ET AL: "Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas; abstract 8516", J. CLIN. ONCOL. SUPPL., [Online] vol. 33, 2015, 2015 ASCO Annual Meeting Retrieved from the Internet: URL:http://http://meetinglibrary.asco.org/ content/152821-156> [retrieved on 2015-12-21] (B1)

SEBESTYEN ET AL.: 'Human TCR that incorporate CD3zeta induce highly preferred patring between TCRalpha and beta chains following gene transfer.' J IMMUNOL. vol. 180, no. 11, 2008, pages 7735 - 7746, XP055118197 (B1)

SEOK JUNHEE ET AL: "Genomic responses in mouse models poorly mimic human inflammatory diseases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, no. 9, February 2013 (2013-02), pages 3507-3512, ISSN: 0027-8424 (B1)

SHANKS NIALL ET AL: "Are animal models predictive for humans?", PHILOSOPHY, ETHICS, AND HUMANITIES IN MEDICINE, BIOMED CENTRAL LTD, LO, vol. 4, no. 1, 15 January 2009 (2009-01-15), page 2, XP021052033, ISSN: 1747-5341, DOI: 10.1186/1747-5341-4-2 (B1)

Supplementary Materials to D2 (B1)

TAMMANA SYAM ET AL: "4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies", HUMAN GENE THERAPY, vol. 21, January 2010 (2010-01), pages 75-86, XP002732432, (B1)

US-A1- 2004 043 401 (B1)

US-A1- 2009 297 994 (B1)

US-B1- 6 410 319 (B1)

US-B2- 7 265 209 (B1)

US-B2- 7 319 143 (B1)

US-B2- 7 446 190 (B1)

US-B2- 7 448 191 (B1)

US-B2- 7 514 537 (B1)

WO-A1-2010/025177 (B1)

WO-A2-2009/091826 (B1)

CALL ET AL.: 'The T cell receptor: critical role of the membrane environment in receptor assembly and function.' ANNU REV LMMUNOL. vol. 23, 2005, pages 101 - 125, XP002396081 (B1)